Edgewise Therapeutics Inc., a leading biopharmaceutical company focused on muscle diseases, announced new compensation terms as part of their 2024 Inducement Equity Incentive Plan. On July 31, 2025, the company granted inducement stock options to purchase 84,250 shares and inducement restricted stock units (RSUs) covering 5,000 shares to three new non-executive employees. The stock options have an exercise price of $14.26 per share, the closing price on the grant date. They will vest with 25% of the shares on the first anniversary of the employees' start date, and 1/48th of the shares monthly thereafter. The RSU awards will vest in equal annual installments over four years, starting on July 31, 2025, contingent on the employees' continued service. These grants are aligned with Nasdaq Listing Rule 5635(c)(4).